09/09/2015
Thyroid Cancers In Children
The New Dawson-Hurtt/Robinson “AMERICA TEST” – “Testing for life threatening endocrine and respiratory diseases just got simpler.”
Records show that thirty nine (39) months after the multiple explosions at Fukushima, thyroid cancer rates among nearby children had skyrocketed to more than forty times (40x) normal. More than 48 percent of some 375,000 young people—nearly 200,000 kids—tested by the Fukushima Medical University near the smoldering reactors now suffer from pre-cancerous thyroid abnormalities, primarily nodules and cysts. Since then, more than 120 childhood cancers have been indicated where just three would be expected, says Joseph Mangano, executive director of the Radiation and Public Health Project.
The deadly epidemic at Fukushima is consistent with impacts suffered among children near the 1979 accident at Three Mile Island and the 1986 explosion at Chernobyl, as well as findings at other commercial reactors. The likelihood that atomic power could cause such epidemics has been confirmed by the Canadian Nuclear Safety Commission, which says that “an increase in the risk of childhood thyroid cancer” would accompany a reactor disaster.
US HEAT Corporation believes the use of zeolites along with electromagnetic (EMI) and Cs and Sr radioisotope absorbing air filtration and face mask and respirator products are essential for children living near a nuclear reactor accident.
The New Dawson-Hurtt/Robinson “AMERICA TEST” – “Testing for life threatening endocrine and respiratory diseases just got simpler” (1).
Over the past three decades, medical scientists at the U.S. National Cancer Institutes (NCI) at the National Institutes of Health (NIH) have pursued and identified surrogate metabolite biomarkers found in urine, blood, plasma and tissue samples (using mass spectrometers). Some of these surrogate metabolite biomarkers i.e. Cortisol Sulphate and Creatinine Riboside show promise as biomarkers of pre-neoplastic development or for early malignant transformation of lung cancers and for patient progress monitoring and prognosis (2).
The new America Test focuses on the latter use of the aforementioned biomarkers and the subsequent pre-procedural and pre-therapeutic clinical laboratory examination (ICD-10 CM V72.63) and analysis of the [biopsied] tumor cells and its responses to specific anti-cancer drugs using a general purpose clinical laboratory instrument (the Bactobridge – USP # 6426212 & 6476622, Robinson, et al).
This proprietary instrument has been in use since the 1960s (USP # 3781659) (3) and listed with the US FDA since the 1990s (A787088) for monitoring the metabolism of human tumor cells i.e., ovarian, endometrial and breast cancer cells (4). Most important, it was used at NIH to calculate and determine quantal dose responses from standard chemotherapeutic agents, i.e., Flurouracil, 8-Azaguanine and BCNU, etc., against human tumors in vitro. Identification of drugs that selectively inhibit the growth of particular cancer cells, from individual patients can be achieved (5).
The new America Test shows that the combination of citric acid and colloidal silver is too important to not be a part of any realistic antiviral/antimicrobial prophylaxis against disease causing pathogenic agents (for which no vaccinations exist) and human cancers. Colloidal silver has been proven to kill MCF-7 breast cancer cells and combined with citric acid and zinc will inactivate the following:
• low and high pH viruses such as the Influenza and MERS & SARS causing Coronaviruses, and
• bacterial cells such as gram negative (legionella pneumophia) and gram positive (bacillus anthracis vegetative cells)
Research studies also support the fact that non-metabolizing Zeolites (such as those used in our system and) traditionally used for removal of heavy metals such as Cd, Hg and Pb will absorb radioisotopes such as thyroid cancer causing Cs and Sr from the human body and support the upregulation (stimulation) of interferon and the natural immune system and that online laboratory instruments such as the Bactobridge and metabolic biomarkers are essential for selective cancer treatment and patient progress monitoring (1).
References:
1. Robinson, W.L., Hurtt, J.R., Hurtt, M.E. & Dawson, R.B.(MD) (Inventors).
2. Harris et al., Non-invasive Urinary Biomarkers Highly Predictive of Non-Small Cell Lung Cancer Status and Survival (E-121-2013/0).
3. Ur, A., Conductivity Measuring System And Conductivity Cells Therefor, (USP # 3,781,659 - 1973).
4. Dawson et al., “Pre-Therapeutic In Vitro (Individualized Patient) Anti-Cancer Drug(s) Response Measurements Using The Bactobridge" [University of Maryland Institutional Review Board (IRB) Exemption No. -039801, Assurance No. M1174-01NR (3/26/98)].
5. Ommaya et al., An Electrical Impedance Method For Rapid Measurement Of Tumor Cell Sensitivity To Anti-Cancer Drugs. Exptl. Clinical Res. VII (5) 641-647 (NIH-1981).
